Search results
Found 6798 matches for
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Oxford Medicine December 2020
Oxford Medicine December 2020
Oxford Medicine Spring Summer 2021
Oxford Medicine Spring Summer 2021
Oxford Medicine Summer 2022
Oxford Medicine Summer 2022
Oxford Medicine Magazine - Winter 2023
Oxford Medicine Magazine - Winter 2023
Oxford Medicine Autumn Winter 2021
Oxford Medicine Autumn Winter 2021